All data are based on the daily closing price as of August 25, 2025
t
Takara Bio
4974.TSE
6.50 USD
-0.06
-0.91%
Overview
Last close
6.50 usd
Market cap
782.49M usd
52 week high
7.68 usd
52 week low
4.93 usd
Target price
8.31 usd
Valuation
P/E
112.3272
Forward P/E
N/A
Price/Sales
2.5627
Price/Book Value
1.0763
Enterprise Value
604.04M usd
EV/Revenue
1.9751
EV/EBITDA
13.6899
Key financials
Revenue TTM
311.07M usd
Gross Profit TTM
181.42M usd
EBITDA TTM
46.14M usd
Earnings per Share
0.06 usd
Dividend
0.12 usd
Total assets
840.66M usd
Net debt
-190.81M usd
About
Takara Bio Inc., together with its subsidiaries, engages in the businesses of reagents, equipment, contract services, and genetic medicine in Japan, China, the rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including reagents needed for genetic and cellular research, PCR instruments, cellular analysis devices, and in vitro diagnostics for COVID-19 testing. It also provides contract services related to regenerative medicine products and contract services related to gene analysis and testing. In addition, the company is involved in commercialization of its proprietary platform technology for biologics development; development, manufacture, and sale of manufacture ancillary materials, such as RetroNectin that is used in the manufacture of gene therapy product; application for marketing authorization of NY-ESO-1 siTCR gene therapy product; and development of JAK/STAT technology suitable for CAR gene therapy and applied development of CereAAV", a brain-tropic adeno-associated virus vector. It provides its products and services through sales agents or directly to its customers. The company was incorporated in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.